The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Doxycycline Prophylaxis to Reduce Incident Syphilis among HIV-Infected Men Who Have Sex With Men Who Continue to Engage in High-Risk Sex: A Randomized, Controlled Pilot Study
Open accessAbstract
BACKGROUND: Incident syphilis infections continue to be especially prevalent among a core group of HIV-infected men who have sex with men (MSM). Because of synergy between syphilis and HIV infections, innovative means for controlling incident syphilis infections are needed. METHODS: Thirty MSM who had syphilis twice or more since their HIV diagnosis were randomized to receive either daily doxycycline prophylaxis or contingency management (CM) with incentive payments for remaining free of sexually transmitted diseases (STDs). Participants were tested for the bacterial STDs gonorrhea (Neisseria gonorrhoeae), chlamydia (Chlamydia trachomatis) and syphilis at weeks 12, 24, 36, and 48 and completed a behavioral risk questionnaire during each visit to assess number of partners, condom use, and drug use since the last visit. Generalized linear mixed models were used to analyze differences between arms in STD incidence and risk behaviors at follow-up. RESULTS: Doxycycline arm participants were significantly less likely to test positive for any selected bacterial STD during 48 weeks of follow-up (odds ratio, 0.27; confidence interval, 0.09-0.83) compared with CM arm participants (P = 0.02).There were no significant self-reported risk behavior differences between the doxycycline and CM arms at follow-up. CONCLUSIONS: Daily doxycycline taken prophylactically was associated with a decreased incidence of N. gonorrhoeae, C. trachomatis, or syphilis incident infections among a core group of HIV-infected MSM at high risk for these infections. Safe and effective biomedical tools should be included in the efforts to control transmission of syphilis, especially in this population. A randomized clinical trial should be conducted to confirm and extend these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That study demonstrated a 73% reduction in any bacterial STI at any site, without substantial differences in sexual behavior.”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Doxycycline taken as STI PrEP as 100 mg orally once daily also demonstrated a substantial reduction in gonorrhea, chlamydia, and syphilis among MSM (90).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [90]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, C., Bayer, A. S., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,260
Fleming, D. T., & Wasserheit, J. N. (1999) · Sexually Transmitted Infections · doi:10.1136/sti.75.1.3 · Cited by 2,271
Marks, G. B., Crepaz, N., Senterfitt, J. W., & Janssen, R. S. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000151079.33935.79 · Cited by 1,223
Buchacz, K. A., Patel, P., Taylor, M. M., Kerndt, P. R., Byers, R. H., Holmberg, S. D., & Klausner, J. D. (2004) · AIDS · doi:10.1097/00002030-200410210-00012 · Cited by 445
Self-citationDynamics and Control of the Transmission of Gonorrhea
Yorke, J. A., Hethcote, H. W., & Nold, A. (1978) · Sexually Transmitted Diseases · doi:10.1097/00007435-197804000-00003 · Cited by 418
An Efficacy Trial of Doxycycline Chemoprophylaxis against Leptospirosis
Takafuji, E. T., Kirkpatrick, J. W., Miller, R. N., Karwacki, J. J., Kelley, P. W., Gray, M. R., McNeill, K. M., Timboe, H. L., Kane, R. E., & Sánchez, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100805 · Cited by 312
HIV transmission rates from persons living with HIV who are aware and unaware of their infection
Hall, H. I., Holtgräve, D. R., & Maulsby, C. H. (2012) · AIDS · doi:10.1097/qad.0b013e328351f73f · Cited by 291
Jarzebowski, W. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2706 · Cited by 106
Gorbach, P. M., Weiss, R. E., Jeffries, R. A., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181ff9750 · Cited by 85
Self-citationSex Affects the Steady-State Pharmacokinetics of Primaquine but Not Doxycycline in Healthy Subjects
Binh, V. Q., Chinh, N. T., Thanh, N. X., et al. (2009) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.09-0214 · Cited by 43
Diagnosis and antimicrobial treatment ofMycoplasma genitaliuminfection: sobering thoughts
TAYLOR‐ROBINSON, D. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.919220 · Cited by 33
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Molina, J.-M., Charreau, I., Chidiac, C., Pialoux, G., Cua, E., Delaugerre, C., Capitant, C., Rojas-Castro, D., Fonsart, J., Bercot, B., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30725-9 · Cited by 449
Responding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Confronting Rising STIs in the Era of PrEP and Treatment as Prevention
Ramchandani, M. S., & Golden, M. R. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00446-5 · Cited by 84
Tang, E. C., Vittinghoff, E., Philip, S. S., Doblecki-Lewis, S., Bacon, O., Chege, W., Coleman, M. E., Elion, R., Buchbinder, S., Kolber, M. A., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002522 · Cited by 31
Metadata
- Authors
- Bolan, R. K., Beymer, M. R., Weiss, R. E., Flynn, R. P., Leibowitz, A. A., & Klausner, J. D.
- Affiliations
- University of California, Los Angeles (US)
- Los Angeles LGBT Center (US)
- Corresponding author
- Bolan, Robert K.
- Beymer, Matthew R.
- Flynn, Risa P.
- ORCID
- Venue
- Sexually Transmitted Diseases
- Published
- 2015-02
- Volume
- 42
- Issue
- 2
- Pages
- 98-103
- ISSN
- 0148-5717 (ISSN-L)
- PMC
- PMC4295649
- OpenAlex
- W2149986546
- Cited by
- 206
- References
- 11
- Citations by year
- 2026: 14 · 2025: 30 · 2024: 33 · 2023: 36 · 2022: 16 · 2021: 15 · 2020: 13 · 2019: 18 · 2018: 11 · 2017: 10 · 2016: 5 · 2015: 4
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Sexually Transmitted Diseases (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- U.S. Public Health Service (5P30 A1028697)
- National Institute of Mental Health (MH58107, P30MH058107)
- National Institute of Allergy and Infectious Diseases (P30AI028697)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Syphilis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- doxycycline prophylaxis, syphilis incidence, HIV-infected men who have sex with men, contingency management, sexually transmitted infections, gonorrhea, chlamydia, condom use, sexual risk behavior, HIV-syphilis coinfection
- MeSH terms
- Adult, Anti-Bacterial Agents, Doxycycline, Feasibility Studies, Humans, Health Knowledge, Attitudes, Practice, Male, Pilot Projects, Reimbursement, Incentive, Risk-Taking, Sexual Partners, Syphilis, Los Angeles, HIV Infections, Incidence, Prevalence, Condoms, Homosexuality, Male, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
